Last reviewed · How we verify
NCT03267121
A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Phase 2 trial testing Apatinib Mesylate Tablets in Head and Neck Squamous Cell Carcinoma in 38 participants. Completed in 1 November 2020.
30 September 2020
Quick facts
| Lead sponsor | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 38 |
| Start date | 1 October 2017 |
| Primary completion | 30 September 2020 |
| Estimated completion | 1 November 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Apatinib Mesylate Tablets — full drug profile →
- Tegafur Gimeracil Oteracil Potassium Capsules — full drug profile →
Conditions studied
- Head and Neck Squamous Cell Carcinoma — all drugs for Head and Neck Squamous Cell Carcinoma →
Sponsor
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Who can join
Adults 18 to 75, any sex, with Head and Neck Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a non-randomized, phase II, open label study of apatinib mesylate tablets plus tegafur gimeracil oteracil potassium capsules induction chemotherapy in locally advanced squamous cell carcinoma of head and neck patients who were judged surgically unresectable or appropriate for non-surgical definitive therapy.The primary purpose of this study is to evaluate the efficacy of apatinib mesylate tablets plus tegafur gimeracil oteracil potassium capsules in locally advanced squamous cell carcinoma of head and neck
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Efficacy and feasibility of Apatinib and S-1 as a novel oral induction therapy in locally advanced head and neck squamous cell carcinoma: an exploratory phase 2 open-label, single-arm trial.
Jiang W, Li R, Zhang L, Dou S, et al · · 2023 · cited 1× · PMID 37251944 · DOI 10.3389/fonc.2023.1072538
Verify or expand the search:
- PubMed search for NCT03267121
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Apatinib Mesylate Tablets
Trials testing the same drug.
- NCT07314203 — Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastr · Phase 3 · not yet recruiting
- NCT07357532 — Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD · Phase 2 · not yet recruiting
- NCT06759090 — Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT06188455 — Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer · Phase 3 · not yet recruiting
- NCT04714190 — A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression · Phase 3 · unknown
Other recruiting trials for Head and Neck Squamous Cell Carcinoma
Currently open trials in the same condition.
- NCT06980038 — Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone i · Phase 2 · recruiting
- NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
- NCT06995508 — Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial · Phase 2 · recruiting
- NCT07254585 — SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma · Phase 2 · recruiting
- NCT07514754 — Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients · NA · recruiting
Other Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University trials
Trials by the same sponsor.
- NCT07535567 — Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma: · Phase 2, PHASE3 · not yet recruiting
- NCT07505251 — Development and Validation of the Periodontal Map Derived From IOS and CBCT Registration for Diagnosis and Treatment Pla · not yet recruiting
- NCT07466810 — Resection and Defect Repair of Oral Cancer Aided by Mixed Reality Technology · NA · not yet recruiting
- NCT07533695 — Impact of Day 2 Versus Day 3 Fresh Embryo Transfer on Live Birth Rate in Poor-Prognosis Patients · NA · not yet recruiting
- NCT07490561 — The Impact of Assisted Hatching on Pregnancy Outcomes After Vitrified-Warmed Embryo Transfer in Advanced-age Patients · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03267121 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- Last refreshed: 17 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03267121.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing